A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Terminated
Onxeo
Phase 2
2006-01-01
Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with
recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101
is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with
belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
Completed
National Cancer Institute (NCI)
Phase 2
2006-09-01
This phase II trial studies how well belinostat works in treating patients with ovarian
epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that have spread to
other places in the body or ovarian low malignant potential tumors. Belinostat may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Completed
National Cancer Institute (NCI)
Phase 2
2006-01-01
This phase II trial is studying how well PXD101 works in treating patients with relapsed or
refractory aggressive B-cell non-Hodgkin's lymphoma. PXD101 may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to
the cancer.
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Completed
National Cancer Institute (NCI)
Phase 1/Phase 2
2006-05-01
This phase I/II trial is studying the side effects and best dose of belinostat and to see how
well it works in treating patients with liver cancer that cannot be removed by surgery.
Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
